MedTrace Logo

AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations

NCT00918398 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2009-07-30

No results posted yet for this study

Summary

The primary objective is to investigate the pharmacokinetics of AZD1981 given in different formulations and to measure renal clearance

Conditions

  • Healthy
  • Postmenopausal
  • Surgically Sterile Women

Interventions

DRUG

AZD1981

100 mg iv infusion, single dose, 4 hours infusion

DRUG

AZD1981

514 mg oral solution, single dose

DRUG

AZD1981

500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose

DRUG

AZD1981

500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose

Sponsors & Collaborators

Principal Investigators

  • Eva Pettersson · AstraZeneca R&D, Lund, Sweden

  • Elisabeth Eden · Quintiles AB, Uppsala, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Completion
2009-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00918398 on ClinicalTrials.gov